Publicaciones en colaboración con investigadores/as de Harvard Medical School (36)

2022

  1. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

    The Lancet Oncology, Vol. 23, Núm. 7, pp. e334-e347

  2. Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma

    Clinical Cancer Research, Vol. 28, Núm. 16, pp. 3537-3545

  3. COPD detection in lung cancer screening programmes: “hitting two birds with one stone”

    European Respiratory Journal

  4. Chest CT-assessed comorbidities and all-cause mortality risk in COPD patients in the BODE cohort

    Respirology, Vol. 27, Núm. 4, pp. 286-293

  5. Comorbidities and mortality risk in adults younger than 50 years of age with chronic obstructive pulmonary disease

    Respiratory Research, Vol. 23, Núm. 1

  6. Effect of Prognostic Guided Management of Patients With Acute Pulmonary Embolism According to the European Society of Cardiology Risk Stratification Model

    Frontiers in Cardiovascular Medicine, Vol. 9

  7. Genetic and pharmacological inhibition of XBP1 protects against APAP hepatotoxicity through the activation of autophagy

    Cell death & disease, Vol. 13, Núm. 2, pp. 143

  8. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism

    Chest, Vol. 161, Núm. 2, pp. 524-534

  9. Inhaled corticosteroids, COPD, and the incidence of lung cancer: a systematic review and dose response meta-analysis

    BMC Pulmonary Medicine, Vol. 22, Núm. 1

  10. Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis

    Hepatology, Vol. 75, Núm. 4, pp. 968-982

  11. Severe exacerbations and mortality in COPD: Importance of both body and mind

    Respirology